Agreement - February 28, 2014
Spain participates in the building of ESS
Spain will contribute with EUR 90 million in the building of the European Spallation Source in Lund, south of Sweden. Sweden and Spain reached an agreement recently that Spain will contribute to the building of ESS with 5 percent, according to a statement from the Government Offices of Sweden. The total cost for ESS is […]
Biotech article - February 27, 2014
Active Biotech reported for economic crime
The Lund-based pharmaceutical company has been reported to the Swedish Economic Crime Authority. Active Biotech is accused to have to misinformed their investors. Allegedly, the firm was aware of the that the MS drug Nerventra should have been stopped but concealed it. On January 25, the company share went down dramatically on the stock market. […]
Uncategorized - February 27, 2014
VTT shows promising results from skin cancer detection study
VTT Technical Research Centre of Finland announce preliminary promising results from its pilot study with a camera to recognise early stages of cancer. VTT has developed a lightweight, handheld, ultra-precision hyperspectral camera for the detection of skin cancers and their precursors. From the surface of the skin, the camera recognises early stages of cancer that are invisible […]
Biotech Business - February 26, 2014
Index Pharmaceuticals raises EUR 15 million
Index Pharmaceuticals has announced the closing of a USD 20 million / EUR 15 million new rights issue. The Swedish biotechnology company expects to report data from a Phase III study with its lead product candidate Kappaproct, which is being developed for the treatment of severe Ulcerative Colitis. The results from the ongoing Phase III study are expected […]
Agreement - February 26, 2014
Saniona collaborates with Pfizer in million dollar agreement
The Danish biotechnology company has announced a drug developement collaboration with the global pharma giant. Saniona, previously known under the name Aniona, focuses on small molecule drug discovery within the ion channel field. The collaboration with Pfizer involves research on pharmaceuticals to treat neurological diseases and makes use of Saniona’s expertise within the ion channel field, […]
Drug Development Pharma - February 25, 2014
FDA approves Myalept to treat rare metabolic disease
The U.S. Food and Drug Administration has approved AstraZeneca’s and Bristol-Myers Squibb’s Myalept as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. The safety and effectiveness of Myalept, an analog of leptin made through recombinant DNA technology, were evaluated in an open-label, […]
